Advertisement

Amyloidosis

  • Pooja Raibagkar
  • Nagagopal Venna
Chapter

Abstract

Amyloidosis refers to a group of hereditary and acquired disorders characterized by accumulation and extracellular deposition of insoluble higher-order oligomers of misfolded proteins in a beta-pleated sheet configuration that specifically bind with Congo red dye and demonstrate green, yellow, or orange birefringence under polarized microscopy. These deposits are found in central and peripheral nervous system in addition to kidneys, heart, liver, skin, musculoskeletal system, lungs, cornea, etc. There are currently 36 different amyloid fibrils identified in humans.

Keywords

Amyloids Amyloidosis Peripheral nervous system Central nervous system Hereditary amyloidosis Acquired amyloidosis Liver transplantation Amyloidogenic oligomers TTR tetramer stabilizing agents Stem cell transplant Alzheimer’s disease Cerebral amyloid angiopathy 

References

  1. 1.
    Amato AA, Russell JA. Neuromuscular disorders. New York/London: McGraw-Hill Medical; 2008.Google Scholar
  2. 2.
    Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s principles of internal medicine. 19th ed. New York: McGraw Hill Education; 2015.Google Scholar
  3. 3.
    Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–96.PubMedCrossRefGoogle Scholar
  5. 5.
    Wang AK, Fealey RD, Gehrking TL, Low PA. Patterns of neuropathy and autonomic failure in patients with amyloidosis. Mayo Clin Proc. 2008;83(11):1226–30.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408–27.PubMedCrossRefGoogle Scholar
  7. 7.
    Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086–97.PubMedCrossRefGoogle Scholar
  8. 8.
    Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet. 1994;31(5):351–4.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Morrow JM, Reilly MM. Early detection of nerve injury in transthyretin-related familial amyloid polyneuropathy. Brain. 2015;138(Pt 3):507–9.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Sasaki H, Yoshioka N, Takagi Y, Sakaki Y. Structure of the chromosomal gene for human serum prealbumin. Gene. 1985;37(1–3):191–7.PubMedGoogle Scholar
  12. 12.
    Koike H, Morozumi S, Kawagashira Y, Iijima M, Yamamoto M, Hattori N, et al. The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid. 2009;16(3):142–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Conceicao I, Gonzalez-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5–9.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Conceicao I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 2007;35(1):116–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Plante-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69(7):693–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009;11(3):257–62.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012;79(6):733–48.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Maury CP. Immunohistochemical localization of amyloid in Finnish hereditary amyloidosis with antibodies to gelsolin peptides. Lab Investig. 1991;64(3):400–4.PubMedGoogle Scholar
  19. 19.
    Tanskanen M, Paetau A, Salonen O, Salmi T, Lamminen A, Lindsberg P, et al. Severe ataxia with neuropathy in hereditary gelsolin amyloidosis: a case report. Amyloid. 2007;14(1):89–95.PubMedCrossRefGoogle Scholar
  20. 20.
    Chastan N, Baert-Desurmont S, Saugier-Veber P, Derumeaux G, Cabot A, Frebourg T, et al. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p.Asp187Tyr mutation in the GSN gene. Muscle Nerve. 2006;33(1):113–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis. 2010;11(3):145–57.PubMedCrossRefGoogle Scholar
  22. 22.
    Li K, Kyle RA, Dyck PJ. Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy. Am J Pathol. 1992;141(1):217–26.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Klein CJ, Vrana JA, Theis JD, Dyck PJ, Spinner RJ, Mauermann ML, et al. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol. 2011;68(2):195–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–43.PubMedCrossRefGoogle Scholar
  25. 25.
    Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl. 2009;15(10):1229–35.PubMedCrossRefGoogle Scholar
  26. 26.
    Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant. 2007;7(11):2597–604.PubMedCrossRefGoogle Scholar
  27. 27.
    Adams D, Cauquil C, Labeyrie C, Beaudonnet G, Algalarrondo V, Theaudin M. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies. Expert Opin Pharmacother. 2016;17(6):791–802.PubMedCrossRefGoogle Scholar
  28. 28.
    Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Plante-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–92.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016;23(3):178–83.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Testro AG, Brennan SO, Macdonell RA, Hawkins PN, Angus PW. Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation. Liver Transpl. 2007;13(7):1028–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Rajkumar SV, Gertz MA, Kyle RA. Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy. Am J Med. 1998;104(3):232–7.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Mauermann ML. Paraproteinemic neuropathies. Continuum (Minneap Minn). 2014;20(5 Peripheral Nervous System Disorders):1307–22.Google Scholar
  33. 33.
    Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis. Hematol Oncol Clin North Am. 1999 Dec;13(6):1211–33, ix.Google Scholar
  34. 34.
    Kelly JJ Jr, Kyle RA, O’Brien PC, Dyck PJ. The natural history of peripheral neuropathy in primary systemic amyloidosis. Ann Neurol. 1979;6(1):1–7.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Adams D, Lozeron P, Theaudin M, Denier C, Fagniez O, Rerat K, et al. Varied patterns of inaugural light-chain (AL) amyloid polyneuropathy: a monocentric study of 24 patients. Amyloid. 2011;18(Suppl 1):98–100.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Luigetti M, Papacci M, Bartoletti S, Marcaccio A, Romano A, Sabatelli M. AL amyloid neuropathy mimicking a chronic inflammatory demyelinating polyneuropathy. Amyloid. 2012;19(1):53–5.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Tracy JA, Dyck PJ. Primary amyloidosis presenting as upper limb multiple mononeuropathies. Muscle Nerve. 2010;41(5):710–5.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Matsuda M, Gono T, Morita H, Katoh N, Kodaira M, Ikeda S. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study. Eur J Neurol. 2011;18(4):604–10.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Gertz MA. Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Am J Hematol. 2016;91(9):947–56.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Blancas-Mejia LM, Ramirez-Alvarado M. Systemic amyloidoses. Annu Rev Biochem. 2013;82:745–74.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Tsunoda I, Awano H, Kayama H, Tsukamoto T, Ueno S, Fujiwara T, et al. Idiopathic AA amyloidosis manifested by autonomic neuropathy, vestibulocochleopathy, and lattice corneal dystrophy. J Neurol Neurosurg Psychiatry. 1994;57(5):635–7.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Perez-de la Fuente T, Fernandez-Jara J, Rodriguez-Urcelay P, Jimenez-Heffernan J, Juarez A. Isolated AA amyloidosis of the radial nerve. Hand (N Y). 2017;12(5):NP136–NP9.CrossRefGoogle Scholar
  43. 43.
    Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol. 2010;6(7):417–29.PubMedCrossRefGoogle Scholar
  44. 44.
    Valleix S, Gillmore JD, Bridoux F, Mangione PP, Dogan A, Nedelec B, et al. Hereditary systemic amyloidosis due to Asp76Asn variant beta2-microglobulin. N Engl J Med. 2012;366(24):2276–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2016;12(4):459–509.CrossRefGoogle Scholar
  46. 46.
    Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–83.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23(4):213–27.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42(3 Pt 1):631–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Apostolova LG. Alzheimer Disease. Continuum (Minneap Minn). 2016;22(2 Dementia):419–34.PubMedPubMedCentralGoogle Scholar
  50. 50.
    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2014;10(6):CD008782.Google Scholar
  52. 52.
    Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC. Martin S. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;3:CD010803.PubMedGoogle Scholar
  53. 53.
    Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317–24.PubMedGoogle Scholar
  54. 54.
    Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379–97.PubMedCrossRefGoogle Scholar
  55. 55.
    Deardorff WJ, Grossberg GT. Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease. Expert Opin Pharmacother. 2016;17(13):1789–800.PubMedCrossRefGoogle Scholar
  56. 56.
    Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9(3):326–31.PubMedCrossRefGoogle Scholar
  57. 57.
    Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18(2):311–24.PubMedCrossRefGoogle Scholar
  58. 58.
    Keage HA, Carare RO, Friedland RP, Ince PG, Love S, Nicoll JA, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol. 2009;9:3.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(Suppl 3):S115–23.PubMedCrossRefGoogle Scholar
  60. 60.
    Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke. 1997;28(7):1418–22.PubMedCrossRefGoogle Scholar
  61. 61.
    Charidimou A, Gang Q, Werring DJ. Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. J Neurol Neurosurg Psychiatry. 2012;83(2):124–37.PubMedCrossRefGoogle Scholar
  62. 62.
    Schneider JA. The cerebral cortex in cerebral amyloid angiopathy. Lancet Neurol. 2016;15(8):778–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Smith EE, Greenberg SM. Beta-amyloid, blood vessels, and brain function. Stroke. 2009;40(7):2601–6.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry. 2011;82(1):20–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Ding J, Sigurethsson S, Jonsson PV, Eiriksdottir G, Meirelles O, Kjartansson O, et al. Space and location of cerebral microbleeds, cognitive decline, and dementia in the community. Neurology. 2017;88(22):2089–97.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Chung CP, Chou KH, Chen WT, Liu LK, Lee WJ, Chen LK, et al. Strictly lobar cerebral microbleeds are associated with cognitive impairment. Stroke. 2016;47(10):2497–502.PubMedCrossRefGoogle Scholar
  67. 67.
    Charidimou A, Peeters A, Fox Z, Gregoire SM, Vandermeeren Y, Laloux P, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke. 2012;43(9):2324–30.PubMedCrossRefGoogle Scholar
  68. 68.
    Salvarani C, Hunder GG, Morris JM, Brown RD Jr, Christianson T, Giannini C. Abeta-related angiitis: comparison with CAA without inflammation and primary CNS vasculitis. Neurology. 2013;81(18):1596–603.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56(4):537–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Martucci M, Sarria S, Toledo M, Coscojuela P, Vert C, Siurana S, et al. Cerebral amyloid angiopathy-related inflammation: imaging findings and clinical outcome. Neuroradiology. 2014;56(4):283–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Salvarani C, Morris JM, Giannini C, Brown RD Jr, Christianson T, Hunder GG. Imaging Findings of Cerebral Amyloid Angiopathy, Aβ-Related Angiitis (ABRA), and Cerebral Amyloid Angiopathy-Related Inflammation: A Single-Institution 25-Year Experience. Medicine (Baltimore). 2016;95(20):e3613.CrossRefGoogle Scholar
  72. 72.
    Charidimou A, Martinez-Ramirez S, Reijmer YD, Oliveira-Filho J, Lauer A, Roongpiboonsopit D, et al. Total magnetic resonance imaging burden of small vessel disease in cerebral amyloid angiopathy: an imaging-pathologic study of concept validation. JAMA Neurol. 2016;73(8):994–1001.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Charidimou A, Jager RH, Fox Z, Peeters A, Vandermeeren Y, Laloux P, et al. Prevalence and mechanisms of cortical superficial siderosis in cerebral amyloid angiopathy. Neurology. 2013;81(7):626–32.PubMedCrossRefGoogle Scholar
  74. 74.
    Charidimou A, Jaunmuktane Z, Baron JC, Burnell M, Varlet P, Peeters A, et al. White matter perivascular spaces: an MRI marker in pathology-proven cerebral amyloid angiopathy? Neurology. 2014;82(1):57–62.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Chao CP, Kotsenas AL, Broderick DF. Cerebral amyloid angiopathy: CT and MR imaging findings. Radiographics. 2006;26(5):1517–31.PubMedCrossRefGoogle Scholar
  76. 76.
    Auriel E, Charidimou A, Gurol ME, Ni J, Van Etten ES, Martinez-Ramirez S, et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol. 2016;73(2):197–202.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, Greenberg SM. Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol. 2009;66(2):245–9.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM. Current state and future directions of neurochemical biomarkers for Alzheimer’s disease. Clin Chem Lab Med. 2007;45(11):1421–34.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology. 2007;68(17):1411–6.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Kimura A, Sakurai T, Yoshikura N, Hayashi Y, Takemura M, Takahashi H, et al. Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation. J Neuroinflammation. 2013;10:39.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Kloppenborg RP, Richard E, Sprengers ME, Troost D, Eikelenboom P, Nederkoorn PJ. Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment. J Neuroinflammation. 2010;7:18.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Mandybur TI, Balko G. Cerebral amyloid angiopathy with granulomatous angiitis ameliorated by steroid-cytoxan treatment. Clin Neuropharmacol. 1992;15(3):241–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Dohrn MF, Rocken C, De Bleecker JL, Martin JJ, Vorgerd M, Van den Bergh PY, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol. 2013;260(12):3093–108.CrossRefGoogle Scholar
  84. 84.
    Cortese A, Vegezzi E, Lozza A, Alfonsi E, Montini A, Moglia A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry. 2017;88(5):457–8.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Mathis S, Magy L, Diallo L, Boukhris S, Vallat JM. Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2012;45(1):26–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Pooja Raibagkar
    • 1
  • Nagagopal Venna
    • 2
  1. 1.Department of NeurologyLahey Hospital & Medical Center, Tufts University School of MedicineBurlingtonUSA
  2. 2.Division of Neuroimmunology and Neuroinfectious Diseases, Advanced General and Autoimmune NeurologyMassachusetts General HospitalBostonUSA

Personalised recommendations